Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.2K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.2K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

219
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
219
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

757
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
757
Angina IV: Management01:26

Angina IV: Management

157
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
157
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

472
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
472
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

500
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
500

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safe Use of Metformin in Mitochondrial Diabetes: Response to Letter to Editor.

AACE endocrinology and diabetes·2026
Same author

Genotype-Phenotype Heterogeneity Among Patients with Lipodystrophy Harboring Rare POLD1 Variants.

The Journal of clinical endocrinology and metabolism·2026
Same author

Leptin Therapy Improves Metabolic Dysfunction in Immune Checkpoint Inhibitor-induced Lipodystrophy.

JCEM case reports·2026
Same author

Mayo Clinic Proceedings and Evolution of Diabetes Management: A Century of Companionship.

Mayo Clinic proceedings·2026
Same author

Cardiometabolic Outcomes after Surgical Remission of Endogenous Hypercortisolism: A Prospective Cohort Study.

The Journal of clinical endocrinology and metabolism·2025
Same author

A recurrent ACAA2 variant causes a dominant syndrome of lipodystrophy, lipomatosis, infantile steatohepatitis, and hypoglycemia.

The Journal of clinical investigation·2025
Same journal

The UK's visa brake will limit Sudan's healthcare recovery.

BMJ (Clinical research ed.)·2026
Same journal

Miscarriage: poor access to care leaves thousands of UK women desperately searching for answers.

BMJ (Clinical research ed.)·2026
Same journal

Amos maternity review: Doctors must work differently as units "no longer fit for purpose," but report is dogged by controversy.

BMJ (Clinical research ed.)·2026
Same journal

WHO's misguided push for complementary and alternative medicine.

BMJ (Clinical research ed.)·2026
Same journal

Why the GMC should not retain a right of appeal against MPTS decisions.

BMJ (Clinical research ed.)·2026
Same journal

Resident doctors' strikes end with latest pay offer accepted.

BMJ (Clinical research ed.)·2026
See all related articles

Related Experiment Video

Updated: Dec 6, 2025

Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

4.5K

Management of hypertriglyceridemia.

Vinaya Simha1

  • 1Division of Endocrinology, Mayo Clinic, Rochester, MN 55905, USA Simha.aj@mayo.edu.

BMJ (Clinical Research Ed.)
|October 13, 2020
PubMed
Summary
This summary is machine-generated.

Hypertriglyceridemia, a common lipid issue, stems from genetics and lifestyle. Management focuses on lifestyle changes and medications to prevent pancreatitis and cardiovascular disease.

More Related Videos

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.5K
Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study
03:05

Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study

Published on: November 21, 2025

187

Related Experiment Videos

Last Updated: Dec 6, 2025

Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

4.5K
Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.5K
Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study
03:05

Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study

Published on: November 21, 2025

187

Area of Science:

  • Endocrinology and Metabolism
  • Lipidology

Background:

  • Hypertriglyceridemia is a prevalent clinical lipid abnormality.
  • Elevated triglycerides often result from polygenic factors and environmental influences, alongside monogenic causes.
  • Secondary contributors include obesity, diabetes, alcohol, and certain medications.

Purpose of the Study:

  • To review genetic and acquired causes of hypertriglyceridemia.
  • To examine current management strategies, including drug and non-drug approaches.
  • To present a practical, step-by-step management plan.

Main Methods:

  • Literature review of genetic and acquired causes.
  • Analysis of evidence for therapeutic interventions.
  • Development of a clinical management strategy.

Main Results:

  • Identified numerous monogenic causes of severe hypertriglyceridemia.
  • Highlighted the interplay of genetics and environment in common cases.
  • Emphasized lifestyle modifications and drug therapy for risk reduction.

Conclusions:

  • Effective management requires addressing secondary causes and lifestyle factors before drug initiation.
  • Treatment goals include pancreatitis risk reduction in severe cases and cardiovascular risk reduction in moderate cases.
  • A structured approach to managing hypertriglyceridemia is crucial for patient outcomes.